Fierce Pharma Asia—Roche’s $2.5B obesity deal; Akeso CEO’s defense; Lawmaker’s reflection on China

Roche is taking a less-trodden path in obesity. Akeso CEO counters concerns over shrinking lung cancer data for ivonescimab. A U.S. congressman says China is "beating us on our ground game" in biotech. Plus more.